Inactive Instrument

Arena Pharmaceuticals

ARNA

US0400476075

Arena Pharmaceuticals Seeks Acquisitions

January 04, 2017 at 05:00 am

Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA) is seeking acquisitions of drugs or drug candidates, technologies, businesses or other assets.

Latest news about Arena Pharmaceuticals

Longboard Pharmaceuticals, Inc. and Arena Pharmaceuticals, Inc. Executes into Second Amendment to That Certain License Agreement	19/09/22	CI
Arena Pharmaceuticals, Inc.(NasdaqGS:ARNA) dropped from S&P Biotechnology Select Industry Index	15/03/22	CI
Arena Pharmaceuticals, Inc.(NasdaqGS:ARNA) dropped from S&P TMI Index	15/03/22	CI
Arena Pharmaceuticals, Inc.(NasdaqGS:ARNA) dropped from S&P Global BMI Index	15/03/22	CI
Pfizer Completes $6.7 Billion Acquisition of Arena Pharmaceuticals	11/03/22	MT
Arena Pharmaceuticals, Inc. Announces Board Changes	11/03/22	CI
Arena Pharmaceuticals, Inc.(NasdaqGS:ARNA) dropped from NASDAQ Biotechnology Index	11/03/22	CI
Arena Pharmaceuticals, Inc.(NasdaqGS:ARNA) dropped from NASDAQ Composite Index	11/03/22	CI
Pfizer Inc. completed the acquisition of Arena Pharmaceuticals, Inc..	10/03/22	CI
Arena Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	23/02/22	CI
Arena Pharmaceuticals Extends Q4 Loss, Reports Higher Revenue	23/02/22	MT
Earnings Flash (ARNA) ARENA PHARMACEUTICALS Reports Q4 Revenue $54,000, vs. Street Est of $0.732M	23/02/22	MT
Earnings Flash (ARNA) ARENA PHARMACEUTICALS Reports Q4 Loss $-2.54, vs. Street Est of $-2.23	23/02/22	MT
Arena Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	23/02/22	CI
Avalo Therapeutics Promotes Neil to Chief Executive, Sullivan to Finance Chief	17/02/22	MT
North American Morning Briefing : Stock Futures -3-	11/02/22	DJ
North American Morning Briefing : Bonds Yields -3-	10/02/22	DJ
HC Wainwright Downgrades Arena Pharmaceuticals to Neutral From Buy; Price Target is $100	09/02/22	MT
Transcript : Arena Pharmaceuticals, Inc. - Shareholder/Analyst Call	02/02/22
North American Morning Briefing : Dow Futures Dip -2-	22/12/21	DJ
Cantor Fitzgerald Downgrades Arena Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $100 From $93	21/12/21	MT
PUMP / DUMP #15 : The week's gainers and losers	17/12/21
North American Morning Briefing :Stocks Seen on Hold as Fed Looms	15/12/21	DJ
Arena's PT Hiked to $100 by RBC in Line With Pfizer's Proposed Bid; Downgraded to Sector Perform as no Deal Hurdles Seen	14/12/21	MT
Citigroup Downgrades Arena Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $100 From $101	14/12/21	MT

Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. The Company's clinical programs include Etrasimod, which is an oral, selective sphingosine 1-phosphate (S1P), receptor modulator, designed to provide systemic and local cell modulation by targeting S1P receptor subtypes one, four and five. Olorinab, an orally available, potent, peripherally acting, selective, full agonist of the CB2 receptor, is an internally discovered investigational drug candidate. APD418 is an adrenergic receptor (AdrR) antagonist and cardiac myotrope designed to regulate myofilament calcium sensitivity in order to improve contractility without inducing the adverse events associated with available inotropes. Temanogrel is a peripherally acting and selective 5HT2a inverse agonist designed to inhibit serotonin (5-HT) mediated amplification of platelet aggregation and vasoconstriction.

Sector

More about the company